Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T18:17:53.313Z Has data issue: false hasContentIssue false
  • English
  • Français

Cambios inmunológicos en un caso de enfermedad de Marchiafava-Bignami: respuesta al tratamiento con amineptina

Published online by Cambridge University Press:  12 May 2020

T. Humbert ,
J.P. Bureau  and
P. Chabrand
T. Humbert
Affiliation:
Servicio de Psiquiatría, Hospital de Ales, 30100 Alé's en Cévennes
J.P. Bureau
Affiliation:
Laboratorio de Biología Celular y de Inmunogenética, Facultad de Medicina, 34000Montpellier
P. Chabrand
Affiliation:
Servicio de Psiquiatría, Hospital de Nímes, 30000Nîmes, Francia
Get access

Resumen

La enfermedad de Marchiafava-Bignami (EMB) es una complicación poco frecuente del alcoholismo crónico. Describimos una forma regresiva de EMB en la que un tratamiento con amineptina mejoró una disminución primaria de células CD4+. No se observaron cambios significativos en el cociente CD4:CD8 en un pequeño número de sujetos con depresión mayor que recibieron este fármaco.

Keywords

enfermedad de Marchiafava-Bignamiclasificación HLA de células T CD4+ CD8+amineptina
Type
Informe de caso
Information
European Psychiatry (Ed. Española) , Volume 2 , Issue 4 , August 1995 , pp. 260 - 265
Copyright
Copyright © European Psychiatric Association 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Alavi, A, Hirschj, LJ. Studies of central nervous system disorders with single-photon emission computed tomography and positron emission tomography: evolution over the past 2 decades. Semin Nucl Med 1991; 21: 58–81.CrossRefGoogle ScholarPubMed
Bagasra, O, Forman, L. Functionnal analysis of lymphocyte subpopulations in experimental cocaine abuse. I. Dose dependent activation of lymphocyte subsets. Clin Exp Immunol 1989; 77: 289–93.Google Scholar
Barnéoud, P, Neveu, PJ, Vitiello, S, Mormède, P, Le Moal, M. Brain neocortex immunomodulation in rats. Brain Res 1988; 474: 394–8.CrossRefGoogle ScholarPubMed
Baron, R, Heuser, K, Marioth, G. Marchiafava-Bignami disease with recovery diagnosed by CT and MRI: demyelisation affects several CNS structures. J Neurol 1989; 236: 364–6.CrossRefGoogle Scholar
Bourrat, C, Tomassi, M, Bochu, M, Kopp, N, Malsch, S. X-ray scanning in Marchiafava-Bignami disease. Rev Neurol 1984; 140: 426–31.Google ScholarPubMed
Delangre, T, Hannequin, D, Clavier, E, Denis, P, Mihout, B, Samson, M. Maladie de Marchiafava-Bignami d'évolution favorable. Rev Neurol 1986; 142: 933–6.Google Scholar
Delay, J, Brion, S, Escourolle, R, Sánchez, A. Rapports entre la dégénérescence du corps callux de Marchiafava- Bignami et la sclérose laminaire corticale de Morel (à propos de 5 observations anatomo-cliniques). Encéphale 1959; 4: 281–311.Google Scholar
De Micco, C,-Toga, M. Le statut immunitaire du système nerveux central. Rev Neurol 1988; 144: 776–88.Google Scholar
Evans, DL, Pedersen, CA, Folds, JD. Major depression and immunity: preliminary evidence of decreased natural killer cell populations. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 739–48.CrossRefGoogle ScholarPubMed
Ferguson, RM, Schmidtke, JR, Simmons, RL. In: Bergsma, D, Goldstein, A, eds. Neurochimical and Immunological Components of Schizophrenia. New York: Alan R Liss, 1978; 18: 379–402.Google Scholar
Heepe, P, Nemeth, L, Brune, F, Grant, JW, Kleihues, P. Marchiafava-Bignami disease. A correlative computed tomography and morphological study. Eur Arch Psychiatr Neurol Sci 1988; 237: 74–9.CrossRefGoogle ScholarPubMed
Humbert, T, De Guilhermier, P, Maktouf, C, Grasset, G, López, FM, Chabrand, P. Marchiafava-Bignami disease. A case studied by structural and functional brain imaging. Eur Arch Psychiatry Clin Neurosa 1992; 242: 69–71.CrossRefGoogle ScholarPubMed
Irwin, M, Caldwell, C, Smith, TL, Brown, S, Schuckit, MA, Gillin, JC. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Arch Gen Psychiatry 1990; 47: 713–9.CrossRefGoogle ScholarPubMed
Kempinsky, WH. Experimental study of distant effects of acute focal brain injury. A study of diaschisis. Arch Neurol Psychiatry 1958; 79: 376–89.CrossRefGoogle ScholarPubMed
Leboyer, M, Osherson, DN, Nosten, M, Roubertoux, P. Is autism associated with anomalous dominance? J Autism Dev Disord 1988; 18: 539–49.CrossRefGoogle ScholarPubMed
Marchiafava, E, Bignami, A. Sopra un alterzione del corpo calloso osservata in sogetti alcoolisti. Riv PatolNervMent 1903; 8: 544–9.Google Scholar
Meuer, SC, Schlossmann, SF, Reinherz, EL. Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize producís of different major histocompatibility complex regions. Proc Nati Acad Sci USA 1982; 79: 4395–9.CrossRefGoogle Scholar
Meyrignac, C, Bokobza, M, Cesaro, P, Degos, JD. Contribution de l'image par résonance magnétique au diagnostic de la maladie de Marchiafava-Bignami. Presse Medícale 1987; 16: 1863–4.Google Scholar
Neveu, PJ. Cerebral neocortex modulation of immune functions. Life Sci 1988; 42: 1917–23.CrossRefGoogle ScholarPubMed
Neveu, PJ. Latéralisation cérébrale et réponse immunitaire. L'Encéphale 1989; XV: 405–8.Google Scholar
Ou, DD, Shen, ML, Luo, YD. Effects of cocaine on the immune system of Balc/C mice. Clin Immunol Immunopathol 1989; 52: 305–12.CrossRefGoogle Scholar
Schleifer, SJ, Keller, SE, Bond, RN, Cohen, J, Stein, M. Major depressive disorder and immunity. Arch Gen Psychiatry 1989; 46: 81–7.CrossRefGoogle ScholarPubMed
Warren, RP, Margaretten, NC, Pace, NC. Immune abnormalities in patients with autism. J Autism Dev Disord 1986; 16: 189–97.CrossRefGoogle ScholarPubMed
Wik, G, Borg, S, Sjorgen, I. Positron emission tomography determination of regional cerebral glucose metabolism in alcohol-dependent men and healthy controls using “C-glucose. Acta Psychiatr Scand 1988; 78: 234–41.Google ScholarPubMed